Video

Dr. Tripathy Discusses Breast Cancer Gene Profiling

Dr. Debu Tripathy from USC Norris Cancer Center Discusses Breast Cancer Gene Profiling

Debu Tripathy, MD, professor of medicine and co-leader of the Women’s Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, discusses the primary ways that multigene profiling is used in early stage breast cancer.

Multigene gene profiling, such as the Oncotype DX score, help determine treatment in patients that are estrogen receptor (ER) positive or progesterone receptor (PR) positive and HER2 neu negative with early stage cancers. The recurrence score is used most in node negative breast cancer because the patients with an intermediate to high recurrence score are a subset of early breast cancer patients that derive the most benefit from chemotherapy.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center